Churg-Strauss syndrome medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Eosinophilic granulomatosis with polyangiitis responds well to treatment with glucocorticoids such as [[prednisone]] when the disease is not in a life threatening state. Patients who present with a life threatening form, are treated with cyclophosphamide together with a glucocorticoid. 
==Medical Therapy==
==Medical Therapy==
Eosinophilic granulomatosis with polyangiitis responds well to treatment with glucocorticoids such as [[prednisone]] when the disease is not in a life threatening state. The dose of glucocorticoid that is given is 1 mg/kg/day for 2-3 weeks. Patients who are unable to taper the dose of glucocorticoid less than 7.5 mg/day for 3 to 4 months. Patients not responding to tapered doses can be given a glucocorticoid-sparing agent. These agents include [[methotrexate]],[[azathioprine]],[[hydroxyurea]], and meclophenalate mofetil.<ref name="pmid15030353">{{cite journal| author=Assaf C, Mewis G, Orfanos CE, Geilen CC| title=Churg-Strauss syndrome: successful treatment with mycophenolate mofetil. | journal=Br J Dermatol | year= 2004 | volume= 150 | issue= 3 | pages= 598-600 | pmid=15030353 | doi=10.1111/j.1365-2133.2003.05807.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15030353  }}</ref> <ref name="pmid25971154">{{cite journal| author=Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V et al.| title=Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. | journal=Eur J Intern Med | year= 2015 | volume= 26 | issue= 7 | pages= 545-53 | pmid=25971154 | doi=10.1016/j.ejim.2015.04.022 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25971154  }}</ref> <ref name="pmid259711543">{{cite journal| author=Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V et al.| title=Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. | journal=Eur J Intern Med | year= 2015 | volume= 26 | issue= 7 | pages= 545-53 | pmid=25971154 | doi=10.1016/j.ejim.2015.04.022 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25971154  }}</ref>   
Eosinophilic granulomatosis with polyangiitis responds well to treatment with glucocorticoids such as [[prednisone]] when the disease is not in a life threatening state. The dose of glucocorticoid that is given is 1 mg/kg/day for 2-3 weeks. Patients who are unable to taper the dose of glucocorticoid less than 7.5 mg/day for 3 to 4 months. Patients not responding to tapered doses can be given a glucocorticoid-sparing agent. These agents include [[methotrexate]],[[azathioprine]],[[hydroxyurea]], and meclophenalate mofetil.<ref name="pmid15030353">{{cite journal| author=Assaf C, Mewis G, Orfanos CE, Geilen CC| title=Churg-Strauss syndrome: successful treatment with mycophenolate mofetil. | journal=Br J Dermatol | year= 2004 | volume= 150 | issue= 3 | pages= 598-600 | pmid=15030353 | doi=10.1111/j.1365-2133.2003.05807.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15030353  }}</ref> <ref name="pmid25971154">{{cite journal| author=Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V et al.| title=Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. | journal=Eur J Intern Med | year= 2015 | volume= 26 | issue= 7 | pages= 545-53 | pmid=25971154 | doi=10.1016/j.ejim.2015.04.022 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25971154  }}</ref> <ref name="pmid259711543">{{cite journal| author=Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V et al.| title=Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. | journal=Eur J Intern Med | year= 2015 | volume= 26 | issue= 7 | pages= 545-53 | pmid=25971154 | doi=10.1016/j.ejim.2015.04.022 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25971154  }}</ref>   


Patients who present with a life threating form, are treated with [[cyclophosphamide]] together with glucocorticoid. The dosage that is given is 1 mg/kg/day for 2-3 weeks and then slowly tapered to a minimal effective dose. Cyclophosphamide is dosed at 2mg/kg/day as an oral or intravenous dose. Cyclophosphamide may also be administered via pulse infusions at 15mg/kg every 2 weeks for the first three infusions, after which cyclophosphamide may be infused every 3 weeks at 15 mg/kg. Cyclophosphamide infusion doses should not exceed 1.2 g. Patients generally receive 6 to 12 pulse infusions of cyclophosphamide.   
Patients who present with a life threatening form, are treated with [[cyclophosphamide]] together with a glucocorticoid. The dosage that is given is 1 mg/kg/day for 2-3 weeks and then slowly tapered to a minimal effective dose. Cyclophosphamide is dosed at 2mg/kg/day as an oral or intravenous dose. Cyclophosphamide may also be administered via pulse infusions at 15mg/kg every 2 weeks for the first three infusions, after which cyclophosphamide may be infused every 3 weeks at 15 mg/kg. Cyclophosphamide infusion doses should not exceed 1.2 g. Patients generally receive 6 to 12 pulse infusions of cyclophosphamide.   


The maintenance therapy of Eosinophilic granulomatosis with polyangiitis that presents as life threating, patients are treated with azathioprine or methotrexate. Treatment with either of these two agents is given as follows:  
The maintenance therapy of Eosinophilic granulomatosis with polyangiitis that presents as life threating, patients are treated with azathioprine or methotrexate. Treatment with either of these two agents is given as follows:  

Revision as of 12:52, 23 November 2016

Churg-Strauss syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Churg-Strauss syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Churg-Strauss syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Churg-Strauss syndrome medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Churg-Strauss syndrome medical therapy

CDC on Churg-Strauss syndrome medical therapy

Churg-Strauss syndrome medical therapy in the news

Blogs on Churg-Strauss syndrome medical therapy

Directions to Hospitals Treating Churg-Strauss syndrome

Risk calculators and risk factors for Churg-Strauss syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2]Associate Editor(s)-in-Chief: Krzysztof Wierzbicki M.D. [3]

Overview

Eosinophilic granulomatosis with polyangiitis responds well to treatment with glucocorticoids such as prednisone when the disease is not in a life threatening state. Patients who present with a life threatening form, are treated with cyclophosphamide together with a glucocorticoid.

Medical Therapy

Eosinophilic granulomatosis with polyangiitis responds well to treatment with glucocorticoids such as prednisone when the disease is not in a life threatening state. The dose of glucocorticoid that is given is 1 mg/kg/day for 2-3 weeks. Patients who are unable to taper the dose of glucocorticoid less than 7.5 mg/day for 3 to 4 months. Patients not responding to tapered doses can be given a glucocorticoid-sparing agent. These agents include methotrexate,azathioprine,hydroxyurea, and meclophenalate mofetil.[1] [2] [3]

Patients who present with a life threatening form, are treated with cyclophosphamide together with a glucocorticoid. The dosage that is given is 1 mg/kg/day for 2-3 weeks and then slowly tapered to a minimal effective dose. Cyclophosphamide is dosed at 2mg/kg/day as an oral or intravenous dose. Cyclophosphamide may also be administered via pulse infusions at 15mg/kg every 2 weeks for the first three infusions, after which cyclophosphamide may be infused every 3 weeks at 15 mg/kg. Cyclophosphamide infusion doses should not exceed 1.2 g. Patients generally receive 6 to 12 pulse infusions of cyclophosphamide.

The maintenance therapy of Eosinophilic granulomatosis with polyangiitis that presents as life threating, patients are treated with azathioprine or methotrexate. Treatment with either of these two agents is given as follows:

Maintenance therapy Azathioprine Methotrexate
2 mg/kg/day 10-30 mg/wk

Either of these treatments can be given after a few days of oral cyclophosphamide or 2 to 3 weeks after pulse administrative doses. The time frame of how long these medications can be administered for is currently unknown; however, 18-24 months of remission have been noted between both of these medications.[4] According to Sanders et al, 2005 at 18 months the relapse rate when using azathioprine was 13.3% and after 5 years the relapse rate was 62.3%.[5]

Rituximab

Currently rituximab in patients with Eosinophilic granulomatosis with polyangiitis in not licensed for use and studies are required to test for its effectiveness.

Intravenous Immunoglobulins

In Eosinophilic granulomatosis with polyangiitis IV immungoglobulins, are used as a second-line therapy. They are administered with glucocorticoids or together with glucocorticoids + immunosuppressive agents, to patients who experience flare-ups due to certain medications they take or during pregnancy.

References

  1. Assaf C, Mewis G, Orfanos CE, Geilen CC (2004). "Churg-Strauss syndrome: successful treatment with mycophenolate mofetil". Br J Dermatol. 150 (3): 598–600. doi:10.1111/j.1365-2133.2003.05807.x. PMID 15030353.
  2. Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V; et al. (2015). "Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management". Eur J Intern Med. 26 (7): 545–53. doi:10.1016/j.ejim.2015.04.022. PMID 25971154.
  3. Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V; et al. (2015). "Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management". Eur J Intern Med. 26 (7): 545–53. doi:10.1016/j.ejim.2015.04.022. PMID 25971154.
  4. Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V; et al. (2015). "Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management". Eur J Intern Med. 26 (7): 545–53. doi:10.1016/j.ejim.2015.04.022. PMID 25971154.
  5. Bosch X, Guilabert A, Espinosa G, Mirapeix E (2007). "Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review". JAMA. 298 (6): 655–69. doi:10.1001/jama.298.6.655. PMID 17684188.

Template:WH Template:WS